Oteseconazole

Brand names: Vivjoa · Active ingredient: Oteseconazole

In short: VIVJOA is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential [see Warnings and Precautions (5.1), Use in Specific Populations (8.3), and Clinical Studies (14)] . If specimens for fungal culture are ob

Forms & strengthsVIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton.
LabelMycovia Pharmaceuticals, Inc.
Label updatedJan 09, 2026

What is Oteseconazole used for?

VIVJOA is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential

[see

Warnings and Precautions (5.1),

Use in Specific Populations (8.3), and

Clinical Studies (14)]

.

If specimens for fungal culture are obtained prior to therapy, antifungal therapy may be instituted before the results of the cultures are known. However, once these results become available, antifungal therapy should be adjusted accordingly.

Oteseconazole dosage

There are two recommended VIVJOA dosage regimens: a VIVJOA-only regimen and a Fluconazole/ VIVJOA regimen. Use one of the following two dosage regimens:

VIVJOA-only dosage regimen

Fluconazole/VIVJOA dosage regimen

.

Administer VIVJOA orally with food

.

Swallow the capsules whole. Do not chew, crush, dissolve, or open the capsules.

For the VIVJOA-only dosage regimen:

On Day 1:Administer VIVJOA 600 mg (as a single dose), then

On Day 2:Administer VIVJOA 450 mg (as a single dose), then

Beginning on Day 14:Administer VIVJOA 150 mg once a week (every 7 days) for 11 weeks (Weeks 2 through 12).

For the Fluconazole/VIVJOA dosage regimen, prescribe fluconazole and:

On Day 1, Day 4, and Day 7:Administer fluconazole 150 mg orally, then

On Days 14 through 20:Administer VIVJOA 150 mg once daily for 7 days, then

Beginning on Day 28:Administer VIVJOA 150 mg once a week (every 7 days) for 11 weeks (Weeks 4 through 14).

How to take Oteseconazole — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Embryo-Fetal Toxicity

Advise patients that VIVJOA is contraindicated in females of reproductive potential and in pregnant women because it may cause fetal harm

[see

Contraindications (4),

Warnings and Precautions (5.1)and

Use in Specific Populations (8.1,

8.3)]

.

Lactation

Advise patients that VIVJOA is contraindicated in lactating women because it may cause harm to the breastfed infant

[see

Contraindications (4),

Warnings and Precautions (5.1)and

Use in Specific Populations (8.2)].

Important Administration Instructions

Advise patients that VIVJOA must be taken with food, and that capsules must be swallowed whole and not chewed, crushed, dissolved, or opened

.

Concomitant Administration with BCRP Transporter Substrates

Advise patients to inform their health care provider if they are taking a BCRP substrate (e.g., rosuvastatin). Concomitant use with VIVJOA may increase the exposure of drugs that are BCRP substrates, which may increase the risk of adverse reactions associated with these drugs

.

Warnings & precautions

Do not take this medicine if: VIVJOA is contraindicated in:

Females of reproductive potential

Pregnant and lactating women

Patients with known hypersensitivity to oteseconazole.

VIVJOA is contraindicated in females of reproductive potential, and in pregnant and lactating women. Based on animal studies, VIVJOA may cause fetal harm. The drug exposure window of approximately 690 days (based on 5 times the half-life of oteseconazole) precludes adequate mitigation of the embryo-fetal toxicity risks. Ocular abnormalities were observed in the offspring of pregnant rats dosed at 7.5-mg/kg/day during organogenesis through lactation in pre and postnatal developmental studies. The observed ocular abnormalities included cataracts, opacities, exophthalmos/buphthalmos, optic nerve/retinal atrophy, lens degeneration and hemorrhage. Ocular abnormalities occurred at doses about 3.5 times the steady state clinical exposure seen with patients being treated for RVVC. Advise patients that VIVJOA is contraindicated in females of reproductive potential, and in pregnant and lactating women because of potential risks to a fetus or breastfed infant

.

Oteseconazole side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 580 patients were treated with VIVJOA in three clinical trials (Trial 1, Trial 2, and Trial 3)

. Patients in the clinical trials were women with RVVC who received VIVJOA treatment for 12 weeks. The mean age of the patient population was 34 years (range:16-78 years), with 84% of patients aged 18-44 years and 16% of patients aged 45 years and older. Although females of reproductive potential were included in the clinical safety data, VIVJOA is contraindicated in females of reproductive potential due to the risk of embryo-fetal toxicity

[see

Contraindications (4),

Warnings and Precautions (5.1), and

Use in Specific Populations (8.1,

8.3,

8.4)]

.

The clinical trials population was 75% (435/580) White, 17% (96/580) Black or African American, 6% (36/580) Asian, and 2% (13/580) Other women. Fifteen percent (86/580) of all women were Hispanic/Latino. Patients enrolled in the induction and maintenance phases of the clinical trials were treated with different VIVJOA dosage regimens versus comparators

.

The adverse reaction that led to discontinuation in 1 of 580 (0.2 %) VIVJOA-treated patients was allergic dermatitis. …

Drug interactions

BCRP (Breast Cancer Resistance Protein) Transporter Substrates

Oteseconazole is a BCRP inhibitor. Concomitant use of VIVJOA with BCRP substrates (e.g., rosuvastatin) may increase the exposure of BCRP substrates (e.g., rosuvastatin), which may increase the risk of adverse reactions associated with these drugs. Use the lowest possible starting dose of the BCRP substrate or consider reducing the dose of the substrate drug and monitor for adverse reactions

.

About this medicine

VIVJOA (oteseconazole capsules) contains oteseconazole which is an oral azole antifungal agent.

The chemical name of oteseconazole is (

R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1

H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol or 2-Pyridineethanol, α-(2,4-difluorophenyl)-β β-difluoro- α-(1

H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-,(α

R)-. The empirical formula is C

23H

16F

7N

5O

2. The molecular weight is 527.39 g/mol. The structural formula is

Oteseconazole is a white to off-white crystalline powder and is practically insoluble in water within a pH range of 1 to 9 but is soluble in a variety of organic solvents.

Each oteseconazole capsule, for oral use, contains 150 mg oteseconazole and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose, magnesium stearate, silicified microcrystalline cellulose, and sodium lauryl sulfate. Capsule shell and print constituents: FD&C Blue #1, FD&C Red #3, gelatin, Opacode SW-9008/SW-9009 and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e21d5008-800e-4417-927f-14340341865f. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin